A milestone to end a fantastic year! On the final day of 2025 we closed Claret’s 200th portfolio company, marking a proud achievement for our team.
We’re delighted to announce our investment through Fund IV in SIS Medical, a Swiss MedTech company focused on developing, manufacturing, and distributing innovative cardiovascular products, such as the unique Super-High-Pressure Twin-wall Balloon “OPN NC” for coronary calcified plaque modification, supporting the company’s next phase of growth and continued product development.
Headquartered in Frauenfeld, Switzerland, SIS Medical has already achieved significant adoption globally, delivering over 250,000 devices across 50+ countries, while continuing to strengthen its clinical evidence base. Notably, recent results from the VICTORY clinical trial showed that OPN NC performed as well as the current gold-standard treatment used in complex and calcified lesion preparation, reinforcing its position as a safe, effective treatment option lowering healthcare expenses. Combined with in-house manufacturing and an experienced management team, SIS Medical is strongly positioned to capitalise on growing clinical demand. This latest growth funding will enable the company to further scale its commercial footprint in international markets, accelerate R&D pipeline, and build on its strong clinical momentum.
Joey Mason, Life Sciences Venture Partner at Claret comments:
“We are pleased to partner with SIS Medical, whose super-high-pressure twin-wall technology addresses the needs of patients with some of the most challenging coronary conditions. The company’s recent clinical trial showed performance comparable to the gold-standard approach in heavily calcified lesions, reinforcing the strength of the platform. With traction already across Europe, selected international markets and the US, we look forward to supporting the team in the next phase SIS Medical’s growth.”
Dr. Thomas Kraft, CEO of SIS Medical said:
“This partnership marks an important milestone in our company’s development. By joining forces with Claret Capital Partners who share our long-term vision, we are significantly strengthening our ability to scale the business. Their life science expertise, entrepreneurial capabilities, and investor track record will allow us to accelerate commercialization, invest further in innovation, and expand our clinical portfolio. Most importantly, this partnership enables us to execute our growth strategy with greater speed and focus, while staying true to our commitment to improve patient’s life by better lesion preparation after coronary calcification.”
The investment represents a significant milestone for Claret, as our 200th portfolio company since inception, and reinforces our continued commitment to providing tailored, low-dilution capital to innovative companies shaping the future of MedTech and Life Sciences. Here’s to a very active and exciting 2026!
